June 22, 2020 / 3:50 PM / 16 days ago

BRIEF-Kazia Presents Further Paxalisib And Cantrixil Data At Aacr, Reinforcing Positive Efficacy Signals For Both Drugs

June 22 (Reuters) - Kazia Therapeutics Ltd:

* KAZIA PRESENTS FURTHER PAXALISIB AND CANTRIXIL DATA AT AACR, REINFORCING POSITIVE EFFICACY SIGNALS FOR BOTH DRUGS

* KAZIA THERAPEUTICS LTD - PROGRESSION-FREE SURVIVAL FOR PAXALISIB IS 8.5 MONTHS, VERSUS 8.4 MONTHS IN PREVIOUS ANALYSIS

* KAZIA THERAPEUTICS LTD - PAXALISIB OVERALL SURVIVAL (OS) REMAINS AT 17.7 MONTHS, IN LINE WITH ASCO DATA

* KAZIA THERAPEUTICS LTD - CANTRIXIL DATA SHOWS ONE COMPLETE RESPONSE TO TREATMENT, MEANING NO MEASURABLE DISEASE

* KAZIA THERAPEUTICS LTD - NEW RESULTS FOR CANTRIXIL WILL HELP CO TO EXPLORE PARTNERING OPPORTUNITIES OVER H2 OF YEAR

* KAZIA THERAPEUTICS LTD - EXPECTS TO COMPLETE PAXALISB PHASE II STUDY IN 1H CY2021

* KAZIA THERAPEUTICS LTD - FINAL DATA OF CANTRIXIL PHASE I STUDY EXPECTED IN H2 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below